Through the acquisitions and successful integration of Matrix (now Mylan Laboratories Limited) and the former generics business of Merck KGaA in 2007, Mylan has transformed itself from the third largest generic pharmaceuticals company in the U.S. to the third largest generics and specialty pharmaceutical company in the world.
The company offers one of the industry's broadest and highest quality generics product portfolios. Products cover a vast array of therapeutic categories in multiple dosage forms and delivery systems, including oral solids, controlled-release formulations, steriles, injectables, topicals, liquids, transdermals, semi-solids and high-potency products.
Through its India-based subsidiary Mylan Laboratories Limited, Mylan is one of the world's largest manufacturers of active pharmaceutical ingredients (API). Included in Mylan Laboratories Limited’s product portfolio are generic antiretroviral (ARV) APIs, which treat people living with HIV/AIDS. Mylan Laboratories Limited is a leading supplier of generic ARV APIs. And Mylan's specialty business, Mylan Specialty (f/k/a Dey), is a leader in the nebulized respiratory, severe allergy medication and psychiatric therapeutic categories.